GROUP A (2011) | GROUP B (2014) | p-value | |||
---|---|---|---|---|---|
patients (n) | total | 804 | 755 | ||
gender (%) | male | 374 (46.5%) | 388 (51.4%) | .06a | |
female | 429 (53.4%) | 367 (48.6%) | |||
undetermined | 1 (0.1%) | 0 | |||
age (years) | Median (IQR) | 79 (71–86) | 77 (70–83) | <.01b | |
Min – Max | 19–99 | 18–103 | |||
< 65 | 92 (11.4%) | 118 (15.6%) | |||
65–74 | 179 (22.3%) | 170 (22.5%) | |||
≥75 | 533 (66.3%) | 467 (61.9%) | |||
additional diagnosis | at least 1 additional | 750 (93.3%) | 724 (95.9%) | .02a | |
renal insufficiency | 54 (6.7%) | 55 (7.3%) | .66a | ||
coagulopathy | 13 (1.6%) | 17 (2.3%) | .36a | ||
intracranial bleeding | 8 (1.0%) | 6 (0.8%) | .68a | ||
epistaxis | 7 (0.9%) | 10 (1.3%) | .39a | ||
gastrointestinal bleeding | 15 (1.9%) | 12 (1.6%) | .68a | ||
stroke | 43 (5.3%) | 34 (4.5%) | .44a | ||
CHA2DS2-VASC: | 0 | 48 (6.0%) | 56 (7.4%) | .34a | |
1 | 54 (6.7%) | 59 (7.8%) | |||
≥2 | 702 (87.3%) | 640 (84.8%) | |||
prescriptions (per year) | patients with at least 1 prescription | 684 (85.1%) | 677 (89.7%) | <.01a | |
Md (IQR) | 12 (5–25) | 15 (6–24) | .31b | ||
Min - Max | 1–123 | 1–123 | |||
all patients | .02b | ||||
Md (IQR) | 10 (2–22.8) | 13 (3–23) | |||
Min - Max | 0–123 | 0–123 | |||
OAC | VKA or NOAC | 186 (23.1%) | 323 (42.8%) | <.01a | |
VKA | 182 (22.6%) | 188 (24.9%) | .29a | ||
Rivaroxaban | 0 (0.0%) | 121 (16.0%) | <.01a | ||
Dabigatran | 5 (0.6%) | 14 (1.9%) | .03a | ||
Apixaban | 0 (0.0%) | 10 (1.3%) | <.01c | ||
ASA (without additional OAC)d | 123 (15.3%) | 62 (8.2%) | <.01a | ||
consultation of cardiologist | 125 (15.5%) | 165 (21.9%) | <.01a |